We evaluated the incidence and risk factors for hypogammaglobulinemia after allogeneic hematopoietic SCT (HSCT) in pediatric patients. Ig levels were measured pre-transplant, every 2 weeks until day 100 and then monthly post SCT in 185 patients undergoing myeloablative HSCT. Median age was 9 years; 142 (77%) had malignant disease and 114 (62%) received stem cells from an unrelated source. Hypogammaglobulinemia (IgG o500 mg/dL) developed in 143 (77%) of the patients at a median of 56 days (range 15-339) post SCT. The cumulative incidence of hypogammaglobulinemia at 1 year was higher among patients who developed acute GVHD (97% vs 54%, Po0.001), and for those receiving stem cells from an unrelated source (94% vs 51%, Po0.001). The cumulative incidence of TRM was significantly higher for patients with hypogammaglobulinemia (P ¼ 0.026). In multivariable analysis, lower pre-transplant IgG level (Po0.001), younger age (P ¼ 0.012), diagnosis of malignant disease (Po0.001), receiving unrelated SCT (Po0.001) and development of acute GVHD (Po0.001) were all significantly associated with higher risk of hypogammaglobulinemia post HSCT. We conclude that hypogammaglobulinemia is common, following allogeneic HSCT in pediatric patients, especially in those with malignant diseases, those who receive an unrelated transplant or patients who develop GVHD. Keywords: hypogammaglobulinemia; allo-SCT; children; IVIG; IgG; GVHD INTRODUCTION Hematopoietic SCT (HSCT) is an established therapy for various malignant and non-malignant disorders in children. The recovery of the immune system after allogeneic HSCT depends on multiple variables including preparative regimen, age and the presence of GVHD.
INTRODUCTION
Hematopoietic SCT (HSCT) is an established therapy for various malignant and non-malignant disorders in children. The recovery of the immune system after allogeneic HSCT depends on multiple variables including preparative regimen, age and the presence of GVHD. 1 In a study of 93 adult patients, the number of B cell precursors in the BM 1-year post transplant was significantly lower in patients with chronic GVHD. Neither the CD34 þ cell dose, stem cell source (BM vs peripheral blood), donor or patient age were associated with B cell recovery. 2 In another study, low immunoglobulin levels have been associated with decreased survival and increased TRM in adult patients post allogeneic HSCT. In this study, factors associated with low IgG level were age o30 years, female donor to male recipient, not receiving antithymocyte globulin in the preparative regimen and the GVHD prophylaxis regimen. 3 The authors reported a decreased survival and increased TRM in these patients. The slow recovery of immune function post SCT has been linked to poor thymic function. 4 Pediatric patients have more intact thymic function compared with adult patients, which may influence the recovery of B cell function following HSCT. Unlike adult patients, one-third of the pediatric patients undergo an allogeneic HSCT for diseases other than malignancy. Except for patients with primary immune deficiency, those patients have generally an intact immune system prior to transplant. There are no published studies examining the incidence and risk factors for hypogammaglobulinemia post myeloablative allogeneic HSCT in pediatric patients.
MATERIALS AND METHODS
The electronic BMT database at Vanderbilt Children's Hospital contains prospectively collected data on all patients transplanted at our center. We screened the database records of 242 patients who received a myeloablative allogeneic HSCT between August 1999 and January 2012. We excluded 57 patients who underwent a transplant for primary immune deficiency. A total of 185 patients were included in this analysis. For these patients, all available medical records, laboratory values, notes and correspondence were reviewed.
Transplant procedure
All patients included in this study received an allogeneic HSCT. The conditioning regimen consisted of TBI (1320-1440 cGy) and CY 60 mg/kg/ dose for 2 days, or 16 doses of BU (0.8-1 mg/kg) and CY (total dose of 120-200 mg/kg). All patients who received cord blood as the stem source and those with non-malignant diseases received antithymocyte globulin (30 mg/kg) for 3 days. All patients with non-malignant disease received a BU-based preparative regimen. Stem cell source was bone marrow, peripheral blood or cord blood, depending on donor availability. GVHD prophylaxis was with CsA and short-course MTX for all patients, except for those who received cord blood; these patients received CsA and mycophenolate prophylaxis. Tapering of immunosuppression was initiated on day 100 post transplant, with a goal to be tapered off at 6-9 months post transplant unless the patient developed GVHD.
Immunoglobulin measurement and replacement
As part of the standard of care at our center, all patients' IgG levels were measured within 2 weeks of starting the preparative regimen and every 2 weeks post transplant until day 100, and then monthly thereafter. 1 Additional testing was performed at the discretion of the treating physician or as clinically indicated. All patients with an IgG level o500 mg/dL received IVIG replacement at a dose of 0.5 g/kg.
Definitions
Acute and chronic GVHD was diagnosed based on previously published criteria. All patients with acute GVHD grades 2-4 were treated with systemic steroids at a dose of 2 mg/kg for 2 weeks. Then steroids were tapered over 6 weeks. Patients with chronic GVHD were treated with 2 weeks of steroids at 1 mg/kg, and then it was tapered to every other day, dosing over a 6-week period. This dose was maintained for 12 weeks. Patients were then slowly tapered off if they had no active GVHD. TRM was defined as death secondary to any cause not related to disease relapse.
Statistical analyses
This study aims to determine the risk factors for hypogammaglobulinemia in pediatric patients receiving allogeneic HSCT for various diseases. Hypogammaglobulinemia is defined as a drop in the IgG levels o500 mg/dL at any point following transplant. Outcomes of interest included the following: time from transplant until the first IgG o500, time from transplant until death, time from transplant until transplant-related death and patients who require IVIG replacement after 1-year post HSCT. Interested potential risk factors/predictors of interest include sex, age at transplant, malignancy, type of SCT received (for example, matched unrelated donor, mismatched unrelated donor and related donor), stem cell source (for example, BM, cord blood and peripheral blood), conditioning regimen prior to transplant, development of acute GVHD and development of chronic GVHD and IgG levels. Cumulative incidence of the outcomes with 95% confidence interval (CI) and P-value from log-rank test were calculated for type of HSCT, development of acute GVHD and development of chronic GVHD. The time points for assessing the first IgG o500, transplant-related death and OS were 1, 2 and 5 years, respectively. Logistic regression model was used to assess the association between patients who require IVIG replacement after 1-year post HSCT and development of acute/chronic GVHD. The relationship between time from transplant until the first IgG o500 and the aforementioned risk factors was modeled using Cox proportional hazards model. Estimated hazard ratios for each risk factor with 95% CI and P-values were reported. All the statistical analyses were conducted using R v.2.15.1 (http://www. R-project.org/). The Institutional Review Board of Vanderbilt University Medical Center approved this retrospective review of patients' medical records.
RESULTS
A total of 185 patients was included in this analysis, with 107 (58%) male patients and 142 (77%) having a malignant disease. Sixty-two percent of the patients received an allo-SCT from an unrelated source, with BM being the most common stem cell source (69%). A TBI-based preparative regimen was used in 105 patients (57%), whereas a chemotherapy-based regimen was used in the remaining patients. Details of patient characteristics are presented in Table 1 . One hundred and one patients (55%) developed grades 2-4 acute GVHD requiring systemic therapy with steroids, and 51 (28%) developed chronic GVHD requiring systemic immunosuppression. Chronic GVHD was mild in 2, moderate in 28 and severe in 21 patients. One hundred and forty-three (77%) developed hypogammaglobulinemia at a median of 56 days (range 15-339) post HSCT. The cumulative incidence of hypogammaglobulinemia at 100 days post transplant was significantly higher among patients with acute GVHD, as compared with those with no GVHD (85% (95% CI: 76-91) vs 48% (95% CI: 36-57)). The cumulative incidence of hypogammaglobulinemia at 1 year was also significantly higher among recipients of unrelated donor HSCT as compared with those receiving related donor HSCT (94% (95% CI: 87-97) vs 51% (95% CI: 38-61), Po0.001) (Figure 1) . In a multivariable analysis, younger age: hazards ratio (HR) ¼ 0. (Table 2 ). There was significantly higher risk of continued hypogammaglobulinemia, that is, requiring IVIG replacement therapy after a year post transplant, among patients with chronic GVHD HR 112 (95% CI: 23-534, Po0.001).
TRM was significantly higher among the patients who developed hypogammaglobulinemia compared with patients who did not (P ¼ 0.026). The cumulative incidence of TRM at 2 years was 9.8% (95% CI: 4.5-14.6) for patients with hypogammaglobulinemia compared with 0 (95% CI: 0-0) for patients without. Of note, none of the patients who did not develop hypogammaglobulinemia experienced any TRM. Similarly, OS at 5 years post transplant was significantly better for patients who did not develop hypogammaglobulinemia post transplant, as compared with those who did, 85% (95% CI: 75-97) vs 66% (95% CI: 58-75) P ¼ 0.027, respectively (Figure 2) . In a multivariable analysis, there was a trend towards worse OS in patients with malignant disease HR ¼ 2.89 (95% CI: 0.96-8.74, P ¼ 0.06) and those receiving peripheral blood compared with BM as a stem cell source HR ¼ 1.91 (95% CI: 0.92-4.00, P ¼ 0.08). In this model, development of post-transplant hypogammaglobulinemia was not found to be an independent predictor of OS.
DISCUSSION
The aim of our study was to identify risk factors for hypogammaglobulinemia in pediatric patients undergoing myeloablative allogeneic HSCT. Several factors have been associated with the recovery of B cell function post allogeneic HSCT in adults. In one 2 Similarly, the number of B cell precursors at 1-year post transplant was significantly affected by the development of extensive chronic GVHD. The number of B cell precursors post transplant was not associated with the graft's cell dose, the recipient age or the stem cell source. In our study, we found a strong association between the developments of grades 2-4 acute GVHD and of chronic GVHD with the development of hypogammaglobulinemia. Another study that examined the effect of allo-SCT on Ab levels against polio, tetanus, Haemophilus influenza and Streptococcus pneumoniae in 87 adult patients showed that Ab levels against those organisms were primarily affected by the pre-transplant IgG levels in the recipients, and not affected by graft source (marrow vs PBSC), acute GVHD and the use of TBI in the preparative regimen. 5 In our study, a higher pretransplant IgG level was associated with significantly lower risk of developing hypogammaglobulinemia (Po0.001). In a recent study of 179 patients that included 20% pediatric patients, the risk factors identified for hypogammaglobulinemia included the development of acute GVHD, patient age p30, female donor to male recipient, no antithymocyte globulin (ATG) in the preparative regimen and type of GVHD prophylaxis used. 3 The authors did not find any difference between patients with malignant vs nonmalignant disease, although only 9% of the patients included had non-malignant disease. In our analysis, having malignant disease significantly increased the risk of post-HSCT hypogammaglobulinemia despite all the patients with non-malignant diseases receiving ATG as part of their preparative regimen. Age was also identified as a significant factor in our analysis for the development of post-transplant hypogammaglobulinemia, with younger patients being at significantly higher risk (P ¼ 0.012).
The effect of hypogammaglobulinemia and IVIG prophylaxis on major outcomes following allogeneic HSCT has been reported primarily in adult HSCT recipients. 3, [6] [7] [8] [9] [10] [11] In a randomized prospective trial of 382 patients (30% were o20 years of age), the patients received 500 mg/kg weekly IVIG infusions until day 90 and then monthly until 1 year were compared with the control group. 10 The control group had a significantly higher risk of Gramnegative systemic infections, as well as local infections. Among patients X20 years of age, there was an increased risk of acute GVHD and an increased TRM. In the study by Norlin et al., 3 IgG levels were measured at 3, 6 and 12 months post transplant; they showed that the development of a low IgG level at two independent time points was associated with decreased survival. 3 In a placebo-controlled study, 200 patients (21 patients o15 years of age) receiving HLA-identical sibling transplant were randomized to receive placebo, or weekly IVIG at a dose of 50, 250 or 500 mg/kg weekly from day À 7 to day 100 post transplant. 6 In this study, the authors found no difference among the groups in the risk of acute GVHD, TRM or OS. The group that received the higher dose of IVIG had an increased risk of sinusoidal obstruction syndrome. In our analysis, patients receiving HSCT from an unrelated source had more than two-fold risk of developing hypogammaglobulinemia. The survival at 5 years was significantly worse for our patients who developed hypogammaglobulinemia post HSCT. In addition, the TRM was significantly higher among those who developed hypogammaglobulinemia post HSCT, whereas none of the patients who did not develop hypogammaglobulinemia experienced any TRM. The fact that hypogammaglobulinemia was not an independent factor influencing OS in our multivariable analysis is likely related to the fact that all our patients received IVIG infusions in order to maintain a normal IgG level. In this pediatric patient cohort, the current management of hypogammaglobulinemia may mitigate, in part, its impact on OS.
The use of IVIG prophylaxis vs infusions based on levels has not been prospectively studied. In a large retrospective study, the outcome of 115 patients who received IVIG infusions weekly for 3 months post transplant were compared with 114 patients who received IVIG if the IgG level was o400 mg/dL. 8 There was no difference in the incidence of acute GVHD, TRM and infections between the two groups. In a large controlled trial of monthly IVIG prophylaxis between day 90 and 365 post transplant, the authors observed a higher rate of localized infection in the control group but no effect on mortality related to chronic GVHD or OS. 11 The effect of IVIG prophylaxis has not been prospectively studied in pediatric patients receiving allogeneic HSCT. One-third of all pediatric transplants are performed for patients with nonmalignant diseases who we found have significantly lower risk of hypogammaglobulinemia post HSCT. Additionally, the use of cord blood transplant is higher among pediatric patients and this might influence the immune reconstitution. Additional prospective studies are needed in pediatric patients receiving allogeneic HSCT to better define the role of IVIG replacement therapy.
We conclude that hypogammaglobulinemia is common in pediatric patients undergoing allogeneic HSCT. Younger age, pretransplant IgG level, malignant disease, use or unrelated donor stem cell source and development of GVHD are significant risk factors. Prospective trials examining the role of prophylaxis in pediatric patients are needed.
